- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07507747
Testing an Adaptive Intervention for Peer-Supported Mobile Health for Primary Care Veterans With Psychological Distress (Peer mHealth)
Study Overview
Status
Conditions
Detailed Description
Background: Psychological distress in Veterans Affairs (VA) primary care patients is common and often not adequately treated. The VA has a suite of evidence-informed mobile health applications (mHealth apps) for psychological distress that are frequently downloaded, but most Veterans do not use them enough to experience health benefits. Support from helping professionals, such as peer specialists, can increase app use and health benefits. The study team found that peer-supported mHealth is feasible to deliver in VA primary care, increases app engagement and is associated with high satisfaction and improved Veteran health. However, not all individuals need the same amount of support when using mHealth. This study will test an adaptive intervention using a SMART design to match patient need with specific doses of peer support for mHealth.
Significance: The long-term goal is to improve the health of Veterans with psychological distress by developing a brief and efficient stepped-care intervention that can be feasibly implemented in VA primary care settings. This proposal is highly aligned with the priorities of the operational partners in the Offices of Mental Health and Patient Centered Care & Cultural Transformation and VA BBMH. The findings will support the VA-wide expansion of the Peers in PACT program, per recent STRONG Act legislation.
Innovation & Impact: Key innovations include the use of a SMART design to develop an adaptive intervention for a high-priority patient population and the novel application of the Supportive Accountability model in which human support is critical to enhancing adherence to mHealth interventions. The proposal will also provide much needed data on the effectiveness of peers to deliver brief, structured interventions.
Specific Aims: 1) Test the effectiveness of a) stage 1 (Peer mHealth vs. Self-Managed mHealth), b) stage 2 interventions (4 sessions of Peer mHealth vs. Peer Whole Health) among slow responders and c) the embedded stepped-care treatment sequences on psychological distress and secondary outcomes (e.g., app use, cost, mental health service use, symptoms, functioning) at 12 weeks. 2) Examine candidate tailoring variables as predictors of outcomes in a) stage 1 (i.e., motivation, coping self-efficacy) and b) stage 2 (i.e., app use and unmet social needs). Race/ethnicity and sex/gender will also be explored as moderators. 3) Assess barriers and facilitators to implementing adaptive interventions for peer mHealth in PACT by interviewing key VHA leadership, staff and Veteran stakeholders.
Methodology: Participants (N=384) with significant psychological distress who are not engaged in specialty mental health care will be randomized at Stage 1 to receive either Self-Managed mHealth or one peer phone call to support mHealth. Participant response, defined as a reliable decrease in psychological distress (5-point decrease in any DASS-21 subscale) will be measured after 4 weeks. Stage 2 randomization will assign slow responders to step-up to additional mHealth peer phone calls or an alternative peer support model (peer-delivered Whole Health). Stage 1 early responders will continue/ step-down to Self-Managed mHealth. All participants will be reassessed at 12, 16 and 24 weeks post-enrollment. Psychological distress is the primary outcome. Secondary outcomes include app use, mental health service use, cost, psychological symptoms (e.g., depression, anxiety, stress, PTSD, anger, sleep), and functioning (e.g., social functioning).
Next Steps/ Implementation: Should these results support the effectiveness of the adaptive intervention, the investigators will disseminate peer training through the Peers in PACT and Tech into Care VA networks. The investigators will also prepare a new ORD application to systemically investigate how the adaptive intervention can be implemented in VA.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kyle Possemato, PhD
- Phone Number: 53551 (315) 425-4400
- Email: kyle.possemato@va.gov
Study Locations
-
-
California
-
Palo Alto, California, United States, 94304-1207
- VA Palo Alto Health Care System, Palo Alto, CA
-
Contact:
- Jennifer Smith
- Email: Jennifer.Smith@va.gov
-
-
Massachusetts
-
Bedford, Massachusetts, United States, 01730-1114
- VA Bedford HealthCare System, Bedford, MA
-
Contact:
- Andrew Peckham
- Email: Andrew.Peckham@va.gov
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48105-2303
- VA Ann Arbor Healthcare System, Ann Arbor, MI
-
Contact:
- Rebecca Sripada
- Email: Rebecca.Sripada@va.gov
-
-
New York
-
Syracuse, New York, United States, 13210-2716
- Syracuse VA Medical Center, Syracuse, NY
-
Contact:
- Kyle Possemato, PhD
- Phone Number: 53551 315-425-4400
- Email: kyle.possemato@va.gov
-
Principal Investigator:
- Kyle Possemato, PhD
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104-4551
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA
-
Contact:
- Travis Cos
- Email: travis.cos@va.gov
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Veteran enrolled in primary care at one of 3 VA facilities (Philadelphia, PA; Ann Arbor, MI; and Bedford, MA)
- clinically significant psychological distress on at least one DASS-21 subscale (Depression => 10, Anxiety => 8, Stress => 13)
Exclusion Criteria:
- symptoms that may preclude active engagement in the intervention such as gross cognitive impairment or current symptoms of mania or psychosis
- suicide risk as measured by the P4 Suicide Assessment
- plan to engage in psychotherapy during the intervention period
- started or changed the dose of a psychotropic medication in the last two months
- voice a preference to be directly referred to mental health specialty care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Stage 1
Stage 1 randomization
|
Patients use mHealth apps to manage psychological distress
Patients receive one session with a peer while using mHealth apps to manage psychological distress
|
|
Experimental: Stage 2
Stage 2 randomization
|
Patients use mHealth apps to manage psychological distress
Patients receive 4 sessions with a peer while using mHealth apps to manage psychological distress
Patients receive 4 session with a peer focused on Whole Health
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Depression Anxiety and Stress Scale
Time Frame: baseline to 24 weeks
|
Depression Anxiety and Stress Scale is a widely used measure of psychological distress consisting of 21 items measured on a 4-point scale.
The total score ranges from 0-63.
Higher scores indicate greater severity.
|
baseline to 24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Post Traumatic Stess Checklist-5
Time Frame: baseline to 24 weeks
|
Self report measure assessing the 21 symptoms of PTSD on a 5 point scale.
Total score ranges from 0-105.
Higher scores indicate greater severity.
|
baseline to 24 weeks
|
|
Insomnia Severity Index
Time Frame: baseline to 25 weeks
|
Self report measure assessing insomnia with 7 questions on a 5 point scale.
Total score range from 0-28.
Higher scores indicate greater severity.
|
baseline to 25 weeks
|
|
Dimensions of Anger Reactions
Time Frame: baseline to 24 weeks
|
Self report measure assessing anger with 5 items on a 5 point scale.
Total score ranges from 5-25.
Higher scores indicate greater severity.
|
baseline to 24 weeks
|
|
Brief Inventory of Psychosocial Functioning
Time Frame: baseline to 24 weeks
|
Self report measure of psychosocial functioning measured with 7 items on 7 point scale.
Total ranges from 0-42.
Higher scores indicate more dysfunction.
|
baseline to 24 weeks
|
|
Satisfaction with Life Questionnaire
Time Frame: baseline to 24 weeks
|
Self report measure assessing life satisfaction with 5 items on an eight point scale.
Total score ranges from 5-35.
High scores indicate greater satisfaction.
|
baseline to 24 weeks
|
|
Client Satisfaction Questionnaire
Time Frame: baseline to 24 weeks
|
Self report measure assessing participant satisfaction with study interventions with 8 items measures on a 4 point scale.
Total score ranges from 0-24.
Higher scores indicate greater satisfaction.
|
baseline to 24 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
University of Rhode Island Change Assessment
Time Frame: baseline to 24 weeks
|
Self report measure assessing patient motivation to address psychological distress with 12 items on a 5 point scale.
Total score ranges from 12 to 60. Higher scores indicate more motivation.
|
baseline to 24 weeks
|
|
Coping Self Efficacy Scale
Time Frame: baseline to 24 weeks
|
Self report measure to assess patient self efficacy to address psychological distress with 26 items on a 11 point scale.
Total score ranges from 0-260 with higher scores indicating greater self-efficacy.
|
baseline to 24 weeks
|
|
Assessing Circumstances and Offering Resources for Needs
Time Frame: baseline to 24 weeks
|
Measure of unmet social needs that include 11 questions.
The total score ranges from 0-48 with higher scores indicating more unmet needs.
|
baseline to 24 weeks
|
Collaborators and Investigators
Investigators
- Principal Investigator: Kyle Possemato, PhD, Syracuse VA Medical Center, Syracuse, NY
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- HSR4-014-24W
- 1I01RD000522-01A2 (Other Grant/Funding Number: VA ORD)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychological Distress
-
Universita di VeronaUniversity of Roma La SapienzaRecruitingDistress, Emotional | Distress, PsychologicalItaly
-
Utah State UniversityCompletedPsychological Distress | Psychological Flexibility | Psychological Well-BeingUnited States
-
Universidad de las Americas - QuitoRecruitingPsychological DistressEcuador
-
Barbel KnauperNot yet recruitingPsychological DistressCanada
-
Fondation Santé des Étudiants de FranceRecruitingPsychological DistressFrance
-
Fondazione IRCCS Policlinico San Matteo di PaviaCompletedPsychological DistressItaly
-
Azienda Unita Sanitaria Locale di PiacenzaUniversity of Siena, ItalyCompleted
-
International Islamic University MalaysiaCompletedPsychological DistressSingapore
-
George Washington UniversityWorld Health Organization; Transcultural Psychosocial Organization Nepal; Socios... and other collaboratorsCompletedPsychological DistressNepal, Peru, Uganda
-
University of LincolnLincolnshire Partnership NHS Foundation TrustCompletedPsychological DistressUnited Kingdom
Clinical Trials on Self Managed mHealth
-
Daewoong Pharmaceutical Co. LTD.Active, not recruiting
-
University of ChicagoTerminatedHeart Diseases | Heart Failure | Surgery | Cardiac Valve DiseaseUnited States
-
Sheffield Hallam UniversityKing's College London; Sheffield Teaching Hospitals NHS Foundation TrustEnrolling by invitationHeart FailureUnited Kingdom
-
Oslo Metropolitan UniversityOslo University Hospital; Diakonhjemmet Hospital; Keele University; National Institute...Completed
-
Aalborg UniversityCompleted
-
University of the Balearic IslandsMinisterio de Economía y Competitividad, SpainCompleted
-
Muhammed ARCANot yet recruiting
-
Florida International UniversityCenters for Disease Control and Prevention; National Institute for Occupational...Enrolling by invitationSleep Disturbance | Anxiety Symptoms | Depression Symptoms | PTSD SymptomsUnited States
-
Marius HenriksenSection of General Practice, University of Copenhagen; Research Unit for General...Not yet recruitingKnee Osteoarthritis
-
Stanford UniversityNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedOsteoarthritis | Rheumatoid ArthritisUnited States, Canada